New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:22 EDTRXIIRXi Pharmaceuticals announces results of Phase 1 RXI-109 study
RXi Pharmaceuticals announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects. This drug candidate is a highly selective CTGF targeting sd-rxRNA compound that is administered through intradermal injections to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. In this study, 15 volunteers divided over 5 cohorts received single intradermal injections in a dose escalating manner, and blood was drawn at various time points to evaluate the distribution of the drug beyond the injected tissue, into the systemic circulation. Previous primate toxicology work with RXI-109 had shown that the peak blood levels obtained after intradermal injections with 10 mg/kg were approximately 3.5% of the peak levels obtained after intravenous injections with the same dose. With the different doses in the primate study, the dermal and systemic side effects in the animals were minimal. The calculated relative systemic exposure in the 15 volunteers was between 1 and 7% which is very similar to the systemic exposure in primates. As reported earlier, the drug was very well tolerated in all volunteers tested.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
09:03 EDTRXIIRXi Pharmaceuticals and MirImmune enter into exclusive licensing agreement
RXi Pharmaceuticals and privately-held MirImmune announced that they have entered into an exclusive license agreement to RXi's novel and proprietary sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration has the potential to result in novel, more effective and patient friendly cancer treatments that could be a significant step toward personalized medicine. Under the terms of the agreement, MirImmune will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. It will develop cell-based therapeutics utilizing RXi's sd-rxRNA technology to target immune inhibitory pathways which are responsible for limiting the efficacy of cancer immunotherapies. According to the terms, MirImmune will gain access to RXi's sd-rxRNA and rxRNAori® patent families for ex vivo modification of cells for the treatment of cancer. These patents include the composition of the sd-rxRNA and rxRNAori RNAi structures, as well as potential targets for cell-based therapeutics. As consideration for this license, RXi will receive an annual licensing fee, clinical milestone payments, sublicensing income and single digit royalties. Pending MirImmune's achievement of a few gating milestones, RXi will have the right to acquire a double-digit equity stake in MirImmune.
March 23, 2015
07:15 EDTRXIIRXi Pharmaceuticals reports positive advancements in dermatology programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use